RBC Bioscience Corporation(TW:6848)
NT$20.95+0.80 (+3.97%)
TW:6848
RBC Bioscience Corporation financials statements
NT$20.95
At close:+0.80 (+3.97%)
RBC Bioscience Corporation (6848) Ratios
RBC Bioscience Corporation Ratios
TW:6848's free cash flow for Q2 2026 was NT$7.10M. For the 2026 fiscal year, TW:6848's free cash flow was decreased by NT$-1.82M and operating cash flow was NT$8.91M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.25 | 1.41 | 1.41 | 1.27 | 1.41 |
| Quick Ratio | 0.76 | 0.93 | 0.96 | 0.89 | 1.06 |
| Cash Ratio | 0.38 | 0.72 | 0.65 | 0.61 | 0.66 |
| Solvency Ratio | 0.09 | 0.08 | 0.05 | 0.04 | 0.08 |
| Operating Cash Flow Ratio | 0.42 | 0.50 | 0.13 | 0.05 | -0.17 |
| Short-Term Operating Cash Flow Coverage | 1.18 | 0.73 | 0.23 | 0.11 | -0.38 |
| Net Current Asset Value | NT$ -335.69M | NT$ -357.78M | NT$ -372.87M | NT$ -384.84M | NT$ -382.15M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.54 | 0.63 | 0.63 | 0.61 | 0.60 |
| Debt-to-Equity Ratio | 1.46 | 1.92 | 1.96 | 1.94 | 1.99 |
| Debt-to-Capital Ratio | 0.59 | 0.66 | 0.66 | 0.66 | 0.67 |
| Long-Term Debt-to-Capital Ratio | 0.57 | 0.62 | 0.63 | 0.63 | 0.63 |
| Financial Leverage Ratio | 2.70 | 3.06 | 3.13 | 3.18 | 3.30 |
| Debt Service Coverage Ratio | 1.02 | 0.57 | 0.52 | 0.44 | 0.75 |
| Interest Coverage Ratio | 3.61 | 3.47 | 1.45 | 1.02 | 7.68 |
| Debt to Market Cap | 1.62 | 2.11 | 2.48 | 2.56 | 1.35 |
| Interest Debt Per Share | 28.09 | 37.56 | 37.12 | 37.71 | 43.74 |
| Net Debt to EBITDA | 6.94 | 7.20 | 10.96 | 12.63 | 6.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 42.14% | 47.78% | 42.27% | 41.98% | 46.61% |
| EBIT Margin | 15.94% | 18.16% | 10.36% | 7.18% | 16.83% |
| EBITDA Margin | 23.27% | 26.97% | 21.50% | 18.47% | 24.81% |
| Operating Profit Margin | 15.94% | 17.44% | 8.43% | 4.46% | 19.35% |
| Pretax Profit Margin | 13.56% | 13.14% | 4.56% | 2.83% | 14.31% |
| Net Profit Margin | 10.72% | 10.51% | 3.73% | 2.17% | 11.44% |
| Continuous Operations Profit Margin | 10.72% | 10.51% | 3.73% | 2.17% | 11.44% |
| Net Income Per EBT | 79.01% | 79.99% | 81.67% | 76.85% | 79.92% |
| EBT Per EBIT | 85.07% | 75.31% | 54.15% | 63.43% | 73.95% |
| Return on Assets (ROA) | 3.25% | 2.82% | 0.85% | 0.48% | 3.39% |
| Return on Equity (ROE) | 8.77% | 8.65% | 2.67% | 1.52% | 11.19% |
| Return on Capital Employed (ROCE) | 5.57% | 5.49% | 2.22% | 1.16% | 6.95% |
| Return on Invested Capital (ROIC) | 4.18% | 3.92% | 1.67% | 0.81% | 5.06% |
| Return on Tangible Assets | 3.33% | 2.87% | 0.86% | 0.48% | 3.40% |
| Earnings Yield | 9.79% | 9.55% | 3.38% | 2.02% | 7.63% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.07 | 15.22 | 7.50 | 6.80 | 10.18 |
| Payables Turnover | 5.28 | 4.51 | 6.34 | 4.44 | 3.75 |
| Inventory Turnover | 2.68 | 2.03 | 2.24 | 2.14 | 2.62 |
| Fixed Asset Turnover | 0.43 | 0.39 | 0.32 | 0.31 | 0.40 |
| Asset Turnover | 0.30 | 0.27 | 0.23 | 0.22 | 0.30 |
| Working Capital Turnover Ratio | 6.34 | 4.79 | 4.69 | 3.71 | 6.25 |
| Cash Conversion Cycle | 112.49 | 122.73 | 153.91 | 142.32 | 77.91 |
| Days of Sales Outstanding | 45.24 | 23.99 | 48.68 | 53.71 | 35.87 |
| Days of Inventory Outstanding | 136.35 | 179.69 | 162.84 | 170.76 | 139.33 |
| Days of Payables Outstanding | 69.10 | 80.94 | 57.61 | 82.15 | 97.29 |
| Operating Cycle | 181.60 | 203.68 | 211.52 | 224.48 | 175.20 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.84 | 4.30 | 1.02 | 0.51 | -2.14 |
| Free Cash Flow Per Share | 2.39 | 3.50 | 0.52 | -0.27 | -40.20 |
| Dividend Paid and CapEx Coverage Ratio | 3.78 | 2.40 | 0.63 | 0.30 | -0.05 |
| Capital Expenditure Coverage Ratio | 6.30 | 5.42 | 2.04 | 0.66 | -0.06 |
| Operating Cash Flow Coverage Ratio | 0.10 | 0.12 | 0.03 | 0.01 | -0.05 |
| Operating Cash Flow to Sales Ratio | 0.18 | 0.27 | 0.08 | 0.04 | -0.10 |
| Free Cash Flow Yield | 14.17% | 20.19% | 3.55% | -1.84% | -126.33% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.21 | 11.50 | 29.28 | 49.69 | 14.40 |
| Price-to-Sales (P/S) Ratio | 1.09 | 1.10 | 1.10 | 1.08 | 1.50 |
| Price-to-Book (P/B) Ratio | 0.90 | 0.91 | 0.79 | 0.75 | 1.47 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.06 | 4.95 | 28.17 | -54.29 | -0.79 |
| Price-to-Operating Cash Flow Ratio | 5.94 | 4.04 | 14.38 | 28.32 | -14.88 |
| Price-to-Earnings Growth (PEG) Ratio | 1.10 | 0.06 | 0.40 | -0.57 | -0.17 |
| Enterprise Value Multiple | 11.64 | 11.28 | 16.09 | 18.45 | 12.68 |
| Enterprise Value | 595.23M | 624.53M | 596.44M | 592.80M | 789.86M |
| EV to EBITDA | 11.64 | 11.28 | 16.09 | 18.45 | 12.68 |
| EV to Sales | 2.71 | 3.04 | 3.46 | 3.41 | 3.14 |
| EV to Free Cash Flow | 17.46 | 13.69 | 88.44 | -172.13 | -1.66 |
| EV to Operating Cash Flow | 14.69 | 11.17 | 45.16 | 89.78 | -31.22 |
| Tangible Book Value Per Share | 17.61 | 18.17 | 18.31 | 18.99 | 21.45 |
| Shareholders’ Equity Per Share | 18.81 | 19.16 | 18.55 | 19.17 | 21.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.21 | 0.20 | 0.18 | 0.23 | 0.20 |
| Revenue Per Share | 15.39 | 15.77 | 13.29 | 13.40 | 21.24 |
| Net Income Per Share | 1.65 | 1.66 | 0.50 | 0.29 | 2.43 |
| Tax Burden | 0.79 | 0.80 | 0.82 | 0.77 | 0.80 |
| Interest Burden | 0.85 | 0.72 | 0.44 | 0.39 | 0.85 |
| Research & Development to Revenue | 0.08 | 0.05 | 0.06 | 0.09 | 0.07 |
| SG&A to Revenue | 0.18 | 0.26 | 0.27 | 0.29 | 0.21 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.72 | 2.07 | 1.68 | 1.75 | -0.88 |
Currency in TWD
